Developer docs
API playgroundTry for free, no card

Search company profiles

Syrinx Bioanalytics

Full company profile

uuid0022vbm

Namestring
Syrinx Bioanalytics
Legal namestring
Synexa Life Sciences
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Syrinx Bioanalytics is a contract research organization headquartered in Turku, Finland, specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers. The company operates within the Synexa Life Sciences network of three GMP/GCP/GCLP-accredited laboratories located in Manchester (UK), Turku (Finland), and Cape Town (South Africa), employing 200+ staff of which 120+ are scientists with over two decades of cumulative biomarker and bioanalytical experience. The Turku facility specifically is GMP/GLP-accredited for radiopharmaceutical bioanalysis, handling radioisotopes including Ac-225, Th-227, and I-131, with 15+ years of specialized expertise in this niche.

The company delivers a multi-platform technology stack spanning mass spectrometry (LC-MS/MS, ICH M10-validated), immunoassay (MSD, ELISA, RIA), Olink proteomics (Proximity Extension Assay analyzing up to 92 proteins from 1 µL of sample), high-parameter flow cytometry (CLSI H62), ELISpot/Fluorospot, genomics (qPCR, ddPCR, SNP, targeted sequencing), multiplex tissue imaging (immunofluorescence, super-resolution microscopy, CLEM), and dose formulation analysis. Services are organized around three core offerings: translational services that validate therapeutic biology in human disease models prior to clinical entry, soluble biomarker custom panel development for Phase I through approval decisions, and regulated bioanalysis supporting PK, TK, PD, and immunogenicity endpoints. Therapeutic verticals served include autoimmune, oncology, vaccines, biosimilars, ADCs, and cell therapies.

Revenue is generated through professional services delivered as project-based, quote-driven contracts typically structured as multi-year engagements, with pricing varying by study complexity, sample volume, assay type, and regulatory compliance tier. The go-to-market relies on direct enterprise sales using a consultative scientific engagement model, supported by digital content marketing via LinkedIn, YouTube, the Synexa Insights blog, webinars, and industry conferences. The customer base consists of pharmaceutical and biotechnology companies (primary) and vaccine developers, with regulatory credentials including GLP/GCP compliance, GCLP accreditation, ICH M10 validation, GMP certification for radiopharmaceuticals, Gyrolab CRO Certification (June 2025), and My Green Lab highest-level certification (February 2025) forming the core barrier-to-entry for regulated work.

Short descriptiontext

Syrinx Bioanalytics is a Finnish CRO based in Turku specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers, operating within the Synexa Life Sciences global network of three laboratories across the UK, Finland, and South Africa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTurku, Finland
HQ citystring
Turku
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical CRO services, immunogenicity testing, biomarker assay development, biological drug analysis, vaccine bioanalysis
Industry3 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Bioanalytical Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Biomarker Services
TypeProfessional Services
Description

Custom biomarker panel development, validation, and analysis services supporting target engagement, pathway modulation, and disease activity measurement from Phase I through approval

synexagroup.com
2Regulated Bioanalysis
TypeProfessional Services
Description

Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints with GLP/GCP compliance for regulatory submissions

synexagroup.com
3Technology Platform Services
TypeProfessional Services
Description

Specialized analytical services including mass spectrometry, immunoassay, flow cytometry, genomics, proteomics, and tissue imaging delivered as fee-for-service

synexagroup.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Quote-based project pricing for biomarker and bioanalytical services
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based pricing varies by study complexity, sample count, assay type, and regulatory requirements (GLP/GCP vs non-GLP)

synexagroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Syrinx Bioanalytics is a contract research organization (CRO) that provides bioanalysis and immunogenicity testing services for biological drugs, vaccines, and biomarkers. The company develops and validates custom-designed assays across multiple analytical platforms (mass spectrometry, immunoassay, flow cytometry, proteomics, genomics, tissue imaging, and radiopharmaceutical bioanalysis) to support pharmaceutical and biotech clients from discovery through regulatory submission. Operations are anchored in Turku, Finland, with broader laboratory capabilities spanning Manchester, Turku, and Cape Town delivering GLP/GCP/GCLP/ICH M10-compliant services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduce clinical trial risk by validating therapeutic biology in human disease models before entering clinic
+2 more records
Product overview1 text field

Synexa Life Sciences is a biomarker and bioanalytical CRO offering an integrated portfolio of laboratory services organized into three main areas: Translational Services (validating therapeutic biology in human disease models), Soluble Biomarkers and Regulated Bioanalysis (custom assay development and validation), and a suite of technology platforms including Mass Spectrometry, Immunoassay, Proteomics (Olink), Flow Cytometry, ELISpot, Radiopharmaceutical Bioanalysis, Genomics, and Tissue Imaging. The company operates three global laboratories in Manchester, Turku (Finland), and Cape Town with over 200 staff and 120+ scientists, providing end-to-end support from discovery through regulatory submission.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-10
Description

Synexa Life Sciences partnered with Waters Corporation as one of the first bioanalytical laboratories to trial the Xevo TQ Absolute XR Mass Spectrometer. This collaboration enables evaluation of next-generation LC-MS/MS technology for enhanced bioanalytical capabilities in small molecule, peptide, protein, and ADC quantification.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-phase clinical and bioanalytical CRO with strong immunogenicity and PK assay capabilities for biologics and vaccines. Comparable niche focus on regulated bioanalysis supporting small- and large-molecule sponsors.

TypeDirect peer
Description

Specialist bioanalytical CRO providing LC-MS/MS, ligand-binding, and biomarker services supporting PK, immunogenicity, and cell/gene therapy programs. Directly comparable in service mix and customer profile to Syrinx Bioanalytics.

TypeBroad incumbent
Description

Large CRO with substantial bioanalytical and immunogenicity service lines serving biologics and vaccine developers. Comparable in offering but much broader portfolio, scale, and sponsor relationships than Syrinx.

TypeBroad incumbent
Description

Global CRO network offering large-molecule bioanalysis, immunogenicity, and biomarker services as part of a broader laboratory services portfolio. Comparable in assay capabilities but operates at significantly greater scale and geographic reach.

TypeDirect peer
Description

Specialized bioanalytical CRO focused on large-molecule PK, immunogenicity, and biomarker assays for biologics and gene/cell therapies. Closely comparable to Syrinx in modality mix (immunoassay, LC-MS/MS), therapeutic focus, and sponsor base.

TypeBroad incumbent
Description

Full-service CRO with integrated bioanalytical, biomarker, immunogenicity, and central laboratory services for global clinical trials. Comparable capability set but competes via bundled, scale-driven offering.

TypeBroad incumbent
Description

Global CRO/CDMO with growing bioanalytical and biomarker service lines supporting biologics and vaccine programs. Comparable assay capabilities but broader service portfolio and larger scale.

TypeDirect peer
Description

Specialized biologics-focused bioanalytical and GMP testing CRO offering cell-based assays, immunoassays, and lot-release testing for biologics developers. Comparable in modality focus and sponsor profile.

TypeDirect peer
Description

Nordic-origin specialty CRO focused on immunogenicity, biomarker, and cell-based assay services. Highly comparable niche positioning to Syrinx, particularly in regulated immunogenicity testing.

TypeEmerging player
Description

Specialist bioanalytical CRO focused on immunogenicity, ADA, and cell-based assay services for biologics developers. Comparable niche in regulated immunogenicity testing, though smaller and earlier-stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syrinx Bioanalytics

Bioanalytical Contract Research Organization (CRO) Servicessyrinxbioanalytics.com

Syrinx Bioanalytics is a Finnish CRO based in Turku specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers, operating within the Synexa Life Sciences global network of three laboratories across the UK, Finland, and South Africa.

What Syrinx Bioanalytics does

Syrinx Bioanalytics is a contract research organization headquartered in Turku, Finland, specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers. The company operates within the Synexa Life Sciences network of three GMP/GCP/GCLP-accredited laboratories located in Manchester (UK), Turku (Finland), and Cape Town (South Africa), employing 200+ staff of which 120+ are scientists with over two decades of cumulative biomarker and bioanalytical experience. The Turku facility specifically is GMP/GLP-accredited for radiopharmaceutical bioanalysis, handling radioisotopes including Ac-225, Th-227, and I-131, with 15+ years of specialized expertise in this niche.

The company delivers a multi-platform technology stack spanning mass spectrometry (LC-MS/MS, ICH M10-validated), immunoassay (MSD, ELISA, RIA), Olink proteomics (Proximity Extension Assay analyzing up to 92 proteins from 1 µL of sample), high-parameter flow cytometry (CLSI H62), ELISpot/Fluorospot, genomics (qPCR, ddPCR, SNP, targeted sequencing), multiplex tissue imaging (immunofluorescence, super-resolution microscopy, CLEM), and dose formulation analysis. Services are organized around three core offerings: translational services that validate therapeutic biology in human disease models prior to clinical entry, soluble biomarker custom panel development for Phase I through approval decisions, and regulated bioanalysis supporting PK, TK, PD, and immunogenicity endpoints. Therapeutic verticals served include autoimmune, oncology, vaccines, biosimilars, ADCs, and cell therapies.

Revenue is generated through professional services delivered as project-based, quote-driven contracts typically structured as multi-year engagements, with pricing varying by study complexity, sample volume, assay type, and regulatory compliance tier. The go-to-market relies on direct enterprise sales using a consultative scientific engagement model, supported by digital content marketing via LinkedIn, YouTube, the Synexa Insights blog, webinars, and industry conferences. The customer base consists of pharmaceutical and biotechnology companies (primary) and vaccine developers, with regulatory credentials including GLP/GCP compliance, GCLP accreditation, ICH M10 validation, GMP certification for radiopharmaceuticals, Gyrolab CRO Certification (June 2025), and My Green Lab highest-level certification (February 2025) forming the core barrier-to-entry for regulated work.

Syrinx Bioanalytics firmographics

Firmographics
Name
Syrinx Bioanalytics
Legal name
Synexa Life Sciences
Website
https://syrinxbioanalytics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Syrinx Bioanalytics is a Finnish CRO based in Turku specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers, operating within the Synexa Life Sciences global network of three laboratories across the UK, Finland, and South Africa.
Ownership category
akta.pro rank

Syrinx Bioanalytics industry classification

Industry
Product category
Bioanalytical Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Bioanalytical CRO services
  • Immunogenicity testing
  • Biomarker assay development
  • Biological drug analysis
  • Vaccine bioanalysis

Where Syrinx Bioanalytics is headquartered

Location

Headquarters

HQ city
Turku
HQ country
Finland
HQ region
Europe

Offices3 records

Markets served

Syrinx Bioanalytics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Biomarker Services: Custom biomarker panel development, validation, and analysis services supporting target engagement, pathway modulation, and disease activity measurement from Phase I through approval
  2. Regulated Bioanalysis: Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints with GLP/GCP compliance for regulatory submissions
  3. Technology Platform Services: Specialized analytical services including mass spectrometry, immunoassay, flow cytometry, genomics, proteomics, and tissue imaging delivered as fee-for-service

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based project pricing for biomarker and bioanalytical services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Syrinx Bioanalytics product offering

Product offering

Core offering

Syrinx Bioanalytics is a contract research organization (CRO) that provides bioanalysis and immunogenicity testing services for biological drugs, vaccines, and biomarkers. The company develops and validates custom-designed assays across multiple analytical platforms (mass spectrometry, immunoassay, flow cytometry, proteomics, genomics, tissue imaging, and radiopharmaceutical bioanalysis) to support pharmaceutical and biotech clients from discovery through regulatory submission. Operations are anchored in Turku, Finland, with broader laboratory capabilities spanning Manchester, Turku, and Cape Town delivering GLP/GCP/GCLP/ICH M10-compliant services.

Product overview

Synexa Life Sciences is a biomarker and bioanalytical CRO offering an integrated portfolio of laboratory services organized into three main areas: Translational Services (validating therapeutic biology in human disease models), Soluble Biomarkers and Regulated Bioanalysis (custom assay development and validation), and a suite of technology platforms including Mass Spectrometry, Immunoassay, Proteomics (Olink), Flow Cytometry, ELISpot, Radiopharmaceutical Bioanalysis, Genomics, and Tissue Imaging. The company operates three global laboratories in Manchester, Turku (Finland), and Cape Town with over 200 staff and 120+ scientists, providing end-to-end support from discovery through regulatory submission.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Reduce clinical trial risk by validating therapeutic biology in human disease models before entering clinic
  • +2 more outcomes

Companies that use Syrinx Bioanalytics

Customer profile

Segments3 records

Ideal customer profiles3 records

Syrinx Bioanalytics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Syrinx Bioanalytics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Waters CorporationcoreTechnology or Integration · 10 June 2025Synexa Life Sciences partnered with Waters Corporation as one of the first bioanalytical laboratories to trial the Xevo TQ Absolute XR Mass Spectrometer. This collaboration enables evaluation of next-generation LC-MS/MS technology for enhanced bioanalytical capabilities in small molecule, peptide, protein, and ADC quantification.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Syrinx Bioanalytics competitors and assessment

Company assessment

Direct peers

  • Celerion: Early-phase clinical and bioanalytical CRO with strong immunogenicity and PK assay capabilities for biologics and vaccines. Comparable niche focus on regulated bioanalysis supporting small- and large-molecule sponsors.
  • KCAS Bioanalytical & Biomarker Services: Specialist bioanalytical CRO providing LC-MS/MS, ligand-binding, and biomarker services supporting PK, immunogenicity, and cell/gene therapy programs. Directly comparable in service mix and customer profile to Syrinx Bioanalytics.
  • BioAgilytix Labs: Specialized bioanalytical CRO focused on large-molecule PK, immunogenicity, and biomarker assays for biologics and gene/cell therapies. Closely comparable to Syrinx in modality mix (immunoassay, LC-MS/MS), therapeutic focus, and sponsor base.
  • Bionova Scientific: Specialized biologics-focused bioanalytical and GMP testing CRO offering cell-based assays, immunoassays, and lot-release testing for biologics developers. Comparable in modality focus and sponsor profile.
  • Svar Life Science: Nordic-origin specialty CRO focused on immunogenicity, biomarker, and cell-based assay services. Highly comparable niche positioning to Syrinx, particularly in regulated immunogenicity testing.

Broad incumbents

  • Charles River Laboratories: Large CRO with substantial bioanalytical and immunogenicity service lines serving biologics and vaccine developers. Comparable in offering but much broader portfolio, scale, and sponsor relationships than Syrinx.
  • Eurofins Bioanalytical Services: Global CRO network offering large-molecule bioanalysis, immunogenicity, and biomarker services as part of a broader laboratory services portfolio. Comparable in assay capabilities but operates at significantly greater scale and geographic reach.
  • Labcorp Drug Development: Full-service CRO with integrated bioanalytical, biomarker, immunogenicity, and central laboratory services for global clinical trials. Comparable capability set but competes via bundled, scale-driven offering.
  • Pharmaron: Global CRO/CDMO with growing bioanalytical and biomarker service lines supporting biologics and vaccine programs. Comparable assay capabilities but broader service portfolio and larger scale.

Emerging players

  • Immunologix Laboratories: Specialist bioanalytical CRO focused on immunogenicity, ADA, and cell-based assay services for biologics developers. Comparable niche in regulated immunogenicity testing, though smaller and earlier-stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Syrinx Bioanalytics social profiles

Digital presence

Syrinx Bioanalytics compliance and trust

Trust signal

Compliance6 records

Syrinx Bioanalytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syrinx Bioanalytics leadership team

Management profile

Number of profiles

Profiles2 records

Syrinx Bioanalytics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syrinx Bioanalytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syrinx Bioanalytics

What does Syrinx Bioanalytics do?

Syrinx Bioanalytics is a contract research organization (CRO) that provides bioanalysis and immunogenicity testing services for biological drugs, vaccines, and biomarkers. The company develops and validates custom-designed assays across multiple analytical platforms (mass spectrometry, immunoassay, flow cytometry, proteomics, genomics, tissue imaging, and radiopharmaceutical bioanalysis) to support pharmaceutical and biotech clients from discovery through regulatory submission. Operations are anchored in Turku, Finland, with broader laboratory capabilities spanning Manchester, Turku, and Cape Town delivering GLP/GCP/GCLP/ICH M10-compliant services.

Is Syrinx Bioanalytics a public or private company?

Syrinx Bioanalytics is a private company. It is classified as unknown and is currently operating.

When was Syrinx Bioanalytics founded?

Syrinx Bioanalytics was founded in 2007. It employs 1 to 10 people.

Where is Syrinx Bioanalytics based?

Syrinx Bioanalytics is headquartered in Turku, Finland, in the Europe region.

How does Syrinx Bioanalytics make money?

Three revenue lines are on record. Biomarker Services are the primary driver. The others are regulated Bioanalysis and technology Platform Services.

Who are Syrinx Bioanalytics's main competitors?

Direct peers on record are Celerion, KCAS Bioanalytical & Biomarker Services, BioAgilytix Labs, Bionova Scientific and Svar Life Science. Broad incumbents are Charles River Laboratories, Eurofins Bioanalytical Services, Labcorp Drug Development and Pharmaron. Immunologix Laboratories is listed as an emerging player.

Does Syrinx Bioanalytics have an API?

No public API is recorded for Syrinx Bioanalytics.

What industry is Syrinx Bioanalytics in?

Syrinx Bioanalytics's product category is Bioanalytical Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals